

DAFTAR PUSTAKA

- American Institute for Cancer Research. 2014. *Ovarian Cancer 2014 Report*. [Online] Diakses dari: <http://www.aicr.org/continuous-update-project/reports/ovarian-cancer-2014-report.pdf> [Diakses pada 15 Feb 2016].
- Aziz, M.F. 2009. Gynecological cancer in Indonesia. *Journal of Gynecologic Oncology*, 20(1), pp.8–10.
- Bergmann, T.K., Brasch-Andersen, C., Green, H., Mirza, M.R., Pedersen, R.S., Nielsen, F., *et al.* 2012. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of *paclitaxel* in 92 women with ovarian cancer. *Basic and Clinical Pharmacology and Toxicology*, 110(2), pp.199–204.
- Busmar, B. 2006. *Buku Acuan Nasional Onkologi*. Edisi pertama. Yayasan Bina Pustaka Sarwono Prawirodihardjo, Jakarta.
- Coukos, G., Berchuck, A., & Ozols, R. 2008. *Ovarian Cancer. Advances in Experimental Medicine and Biology*, Vol 622. Springer Science & Business Media, New York.
- Delort, L., Chalabi N., Satih, S., Rabiau N., Kwiatkowski, F., Bignon, Y.J, *et al.* 2008. Association between genetic polymorphisms and ovarian cancer. *Anticancer Research*, 28(5B), pp.3079-3081.
- Donato, M.L., Wang, X., Kavanagh, V.V., & Gershenson, D.M., 2006. Chemotherapy for epithelial ovarian cancer. *Gynecologic Cancer*, pp.188-206.
- Fasching, P.A., Gayther, S., Pearce, L., Schildkraut, J.M., Goode E., Thiel, F., *et al.* 2009. Role of genetic polymorphisms and ovarian cancer susceptibility. *Molecular Oncology*, 3(2), pp.171–181.
- Fauzan, R. 2009. Gambaran Faktor Risiko Penggunaan Kontrasepsi terhadap Angka Kejadian Kanker Ovarium di RSUP Dr. Cipto Mangunkusumo Jakarta Berdasarkan Pemeriksaan Histopatologik Tahun 2003-2007. *Skripsi*. Fakultas Kedokteran Universitas Indonesia/Program Studi Pendidikan Dokter Umum.
- Gao, B., Russell, A., Beesley, J., Chen, X.Q., Healey, S., Henderson, M., *et al.* 2014. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. *Scientific reports*, 4(4669), pp.1-9.
- Gavalas, N.G., Karadimou, A., Dimopoulos, M.A., & Bamias, A. 2010. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. *Clinical and Developmental Immunology*, 2010(2010), pp.1-15.
- Gervasini, G., Carrillo, J.A., Garcia, M., Jose, C.S., Cabailas, A., & Benitez, J. 2006. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. *American Cancer Society*, 107(12), pp.2850-2857.
- Gleicher, N. 2013. Why are reproductive cancers more common in nulliparous women. *Reproductive BioMedicine Online*, 2013(26), pp.416-419.

- Green, H. & Andrew E. 2016. Ovarian cancer. *Medscape*. [Online] diakses dari <http://emedicine.medscape.com/article/255771-overview>, [diakses pada 12 Mei 2016].
- Green, H., Soderkvist, P., Rosenberg, P., Horvath, G., & Peterson, C. 2008. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. *Journal of Pharmaceutical Sciences*, 97(6), pp.2045–2048.
- Green, H., Soderkvist, P., Rosenberg, P., Horvath, G., & Peterson, C. 2006. MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. *Clinical Cancer Research*, 12(3I), pp.854–859.
- Grimm, C., Polterauer, S., Zeillinger, R., Tong, D., Heinze, G., Wolf, A., *et. al.* 2010. Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer. *Anticancer Research*, 30(9), pp.3487–3491.
- Hale, M.L., Burq, T.M., & Steeves, T.E. 2012. Sampling for microsatellite-based population genetic studies: 25 to 30 individuals per population is enough to accurately estimate allele frequencies. *PLoS One*, 7(9), p.e45170.
- Hartono, Suryadi, Sudarmo, R.S., & Romi, M.M. 2011. *Genetika Kedokteran*. Bagian Anatomi Fakultas Kedokteran Universitas Gadjah Mada, Yogyakarta.
- Hodges, L.M., Markova, S.M., Chinn, L.W., Gow, J.M., Kroetz, D.L., Klein, T.E., *et. al.* 2012. A very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). *Pharmacogenet Genomics*, 21(3), pp.152–161.
- Jemal, A., Siegel, R., & Ward, E., 2008. Cancer Statistics, 2008. *Journal Cancer for Doctors*, 58(2), pp.1-452.
- Johnatty, S.E., Beesley, J., Paul, J., Fereday, S., Spurdle, A.B., Webb, P.M., *et. al.* 2008. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. *Clinical Cancer Research*, 14(17), pp.5594–5601.
- Johnatty, S.E., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M.H., *et. al.* 2013. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the ovarian cancer association consortium and the cancer genome atlas. *Gynecologic Oncology*, 131(1), pp.8–14.
- Jorde, L.B. & Wooding, S.P. 2004. Genetic variation, classification and race. *Nature Genetics*, 36(11), pp.528-533.
- Katayama, K., Noguchi K., & Sugimoto, Y. 2014. Regulation of p-glycoprotein/ABCB1/MDR1 in human cancer cells. *New Journal of Science*, dapat diakses di <http://dx.doi.org/10.1155/2014/476974>.
- Kementerian Kesehatan Republik Indonesia. 2015. Situasi Penyakit Kanker. [Online] diakses dari: <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf>, [diakses pada 16 Desember 2016].
- Keshavarz-Maleki, R. & Ahangar, M. 2015. Evaluation of G2677T/A of MDR1 gene by polymerase chain reaction in mazandaran province, iran. *Pharmaceutical and Biomedical Research*: 1(2), pp.54-63.

- Kumar, V., Abbas, A.K., Fausto, N., & Mitchell, R.N. 2007. *Robbins Basic Pathology*. 8th Edition. Elsevier, Philadelphia.
- Elghannam, D.M., Ibrahim, L., Ebrahim, M.A., Azmy, E., & Hakem, H. 2014. Association of MDR1 gene polymorphism (G2677T) with imatinib response in egyptian chronic myeloid leukemia patients. *Hematology*, 19(3):123-128
- Milojkovic, M., Stojnev, S., Jovanovic, I., Ljubisavljevic, S., Stefanovic V., & Sunder-Plassman, R. 2011. Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. *Pharmacological Reports*, 63(3), pp.808–814.
- National Cancer Institute. 2017. *NCI Dictionary of Cancer Terms: complete response*. [Online], diakses dari: <https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45652>, [diakses pada 20 Jan 2017].
- Oemiati, R., Rahajeng, E., & Kristanto, A.Y. 2011. Prevalensi tumor dan beberapa faktor yang mempengaruhinya di Indonesia. *Buletin Penelitian Kesehatan*, 39(4), pp.190–204.
- Pasternak, J. J. 2015. *An Introduction to Human Molecular Genetics: Mechanisms of Inherited Diseases*. 2nd edition. Wiley-Liss, Canada.
- Pechandova, K., Buzkova, H., Slanar, O., & Perlik, F. 2006. Polymorphisms of the MDR gene in the czech population. *FoliaBiologica*, pp.184-189
- Raja, F.A., Chopra, N., & Ledermann, J.A. 2012. Optimal first-line treatment in ovarian cancer. *Annals of Oncology*, 23(10), pp.118-127.
- Reeves, G.K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. 2007. Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. *British Medical Journal*, 335(7630), pp.1-11
- Robert, J. 1999. Multidrug resistance in oncology: diagnostic and therapeutic approaches. *Eur J Clin Invest*, 29(6), pp.536–545.
- Roett, M.A. & Evans, P. 2009. Ovarian cancer: an overview. *American Family Physician*, 80(6), pp.609-616.
- Saidijam, M., Mahjub, H., Shahab, N., & Yadegarazari, R. 2015. Simultaneous analysis of multidrug resistance 1 (MDR1) C3435T, G2677T/A, and C1236T genotypes in hamadan city population, west of iran. *Iran Biomed J*. 19(1), pp.57–62.
- Sakaeda, T. 2005. MDR1 genotype-related pharmacokinetics: fact of fiction?. *Drug Metabolism Pharmacokinetic*, 20(6), pp.391-414.
- Sastroasmoro, S. & Ismael, S. 2011. *Dasar-Dasar Metodologi Penelitian Klinis*. Edisi keempat. Sagung Seto, Jakarta.
- Schorge, J.O., Schaffer, J.I., Halvorson, L.M., Hoffman, B.L., Bradshaw, K.D., & Cunningham, F.G. 2008. *Williams Gynecology*. The McGraw-Hill Companies, United State.
- Schuijjer, M. & Berns, E.M.J.J. 2003. TP53 and ovarian cancer. *Human Mutation*, 21(3), pp.285–291.
- Scotto, K.W. 2003. Transcriptional regulation of ABC drug transporters. *Oncogene*, 22(47), pp.7496–7511.

- Sharom, F.J. 2006. *Multidrug resistance protein: P-glycoprotein. Drug Transporters.* [Online], diakses dari: <http://onlinelibrary.wiley.com/doi/10.1002/9780470140505.ch10/pdf>, [diakses pada 15 Okt 2016].
- Sheu, M.J., Teng, Y.N., Chen, Y.Y., & Hung, C.C. 2014. The functional influences of common ABCB1 genetic variants on the inhibition of P-glycoprotein by antrodia cinnamomea extracts. *PLoS ONE*, 9(2), pp.89622.
- Sihombing, M. & Sirait, A.M. 2001. Angka ketahanan hidup penderita kanker ovarium di rs dr . cipto mangunkusumo jakarta. *Maj Kedok Indon*, 57(10) pp.346–352.
- Soeripto, Jensen, O.M., & Muir, C.S.1977. Cancer in yogyakarta, indonesia: relative frequencies. *Br.J.Cancer*, 1977(36), pp.141-148.
- Sorrentino, B.P. 2002. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. *Nature Reviews Cancer*, 2:431-441
- Spentzos, D., Levine, D.A., Kolia, S., Otu, H., Boyd, J., Libermann, T.A., et. al. 2005. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. *Journal of Clinical Oncology*, 23(31), pp.7911–7918.
- Swathi, K., Meghana, M., & Reddy, T.S. 2013. Available online at. , 17(June 2005), pp.33–38.
- Taolin, M. 2014. Terdapat Perbedaan Ekspresi HER-2/NEU pada Kanker Ovarium Derajat Diferensiasi Baik dan Buruk. *Tesis.* Fakultas Kedokteran Universitas Udayana/Program Pascasarjana.
- Tavares-Murta & Murta, E.F.C. 2008. Systemic leucocyte alterations in cancer and their relation to prognosis. *The Open Cancer Journal*, 2, pp.53-58.
- Tecza, K., Pamula-Pilat, J., Kolosza, Z., Radlak, N., & Grzybowska, E. 2015. Genetic polymorphisms and gene-dosage in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy. *Journal of Experimental & Clinical Cancer Research*, 34(2), pp.1-11.
- Tjindarbumi, D. & Mangunkusumo, R. 2002. Cancer in Indonesia, present and future. *Jpn J Clin Oncol* 2012 , 32(Supplement 1), pp.5–7.
- Ullah, M.F. 2008. MINI-REVIEW Cancer Multidrug Resistance (MDR): A major impediment to effective chemotherapy. *Asian Pacific J Cancer Prev*, 9(2008), pp.1–6.
- Vella, N., Aiello, M., Russo, A.E., Scasis, A., Spandidos, D.A., Toffoli, G., et. al. 2011. Genetic profiling and ovarian cancer therapy (review). *Molecular Medicine Reports*, 4(5), pp.771–777.
- Weizmann Institute of Science. 2016. ATP-binding cassette, sub-family B (MDR/TAP), member 1. *Gene Cards Suite.* [Online] diakses dari <http://www.genecards.org/cgi-bin/carddisp.pl?gene=ABCB1>, [diakses pada 16 Mei 2016].
- Winata, I.G.S. 2014. Ekspresi Protein 53 (p53) Tidak Berhubungan dengan Stadium Kanker Ovarium. *Tesis.* Fakultas Kedokteran Universitas Udayana/Program Pascasarjana.

- World Health Organization. 2014. Cancer Country Profiles. [Online] diakses dari http://www.who.int/cancer/country-profiles/idn_en.pdf
- World Health Organization. 2017. Genes and human disease. [Online] diakses dari <http://www.who.int/genomics/public/geneticdiseases/en/index3.html>
- Xu, H., Hong, F., Li, S., Zhang, P., & Zhu, L. 2012. Short hairpin RNA-mediated MDR1 gene silencing increases apoptosis of human ovarian cancer cell line A2780/taxol. *Chinese Journal of Cancer Research*, 24(2), pp.138–142.
- Yan-Hong, L., Yong-Hua, W., Yan, L., & Ling, Y. 2006. MDR1 gene polymorphisms and clinical relevance. *Acta Genetica Sinica*, 33(2), pp.93-104.
- Yan, Z., Chunxia, Q., Lian, L., Xuye, Z., & Yali, L., 2014. Serum HE4 is more suitable as a biomarker than CA125 in chinese women with benign gynecologic disorders. *African Health Sciences*, 14(4), pp. 913-918
- Yang, X., Iyer, A.K., Singh, A., Choy, E., Hornicek, F.J., Amiji, M.M., *et. al.* 2015. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. *Scientific Reports*, 5(8509), pp.1-9.